• CircRHOBTB3 Suppresses Prostate Cancer via NONO-MAOA Regulat

  2026-08-04

  This study identifies circRHOBTB3 as a key tumor suppressor in prostate cancer, demonstrating its ability to inhibit proliferation and metastasis by modulating NONO-mediated MAOA transcription. The findings provide mechanistic insight into circRNA function and suggest circRHOBTB3 as a promising biomarker and therapeutic target for metastatic prostate cancer.

• CTP Solution in p21 mRNA-LNP Bladder Cancer Therapy: Strateg

  2026-08-03

  This article bridges mechanistic insight and translational strategy for researchers developing mRNA-LNP therapies for bladder cancer. Anchored by the landmark study on intravesical p21 mRNA–LNP delivery and the pivotal role of ultra-pure Cytidine-5'-triphosphate, we dissect the requirements for robust, scalable mRNA synthesis and actionable protocol enhancements. We contextualize APExBIO’s CTP Solution (100 mM) as an enabling reagent for next-generation RNA therapeutics, connecting molecular quality to clinical relevance.

• Optimizing Bowel Preparation: Elobixibat Hydrate in Colonosc

  2026-08-03

  Hotta et al. present a rigorously designed, multicenter, randomized trial protocol comparing a novel bowel preparation regimen using elobixibat hydrate plus sodium picosulfate/magnesium citrate with the conventional split-dose polyethylene glycol/ascorbic acid protocol for outpatient colonoscopy. This study aims to address patient acceptability and efficacy, with direct implications for improving colorectal cancer screening outcomes.

• Novobiocin Sodium: Precision Tools for Antiparasitic & DNA R

  2026-08-02

  Novobiocin Sodium, a potent aminocoumarin antibiotic, empowers researchers to dissect DNA replication, cell death, and antiparasitic mechanisms with high selectivity. This article delivers actionable workflows, protocol tips, and troubleshooting strategies, grounded in the latest evidence for both DNA damage and anti-Toxoplasma gondii studies.

• Microglial Nr4a1 and C3 in TMJ Inflammation-Induced Depressi

  2026-08-01

  This study identifies microglial Nr4a1 deficiency and neuronal C3 deposition as central mediators of hippocampal synaptic loss and depression-like behaviors following TMJ inflammation in mice. The findings reveal a mechanistic bridge between peripheral inflammatory disorders and neuropsychiatric complications, highlighting new molecular targets for translational research.

• WNT Signaling Drives Cholangiocyte Proliferation After Bile

  2026-07-31

  Calder et al. uncover a central role for WNT signaling in driving cholangiocyte proliferation after extrahepatic bile duct obstruction in mice. Their integrative in vivo and in vitro approaches clarify β-catenin–dependent mechanisms and highlight the potential for pathway-targeted interventions in cholangiopathies.

• nPEC Enables Accurate Encapsulation Efficiency in Dual-Loade

  2026-07-31

  A recent study establishes nanoparticle exclusion chromatography (nPEC) as an accurate, universally applicable method for measuring encapsulation efficiency in dual-loaded liposomes containing both hydrophilic and lipophilic drugs. This advancement streamlines combination drug delivery research, ensuring reproducibility and improved formulation quality.

• Trichostatin A (TSA): Epigenetic Modulator for Reliable Cell

  2026-07-30

  This article addresses persistent laboratory challenges in cell viability, proliferation, and cytotoxicity assays by leveraging the robust, data-backed performance of Trichostatin A (TSA) (SKU A8183). Drawing from peer-reviewed studies and validated protocols, we examine how TSA ensures reproducibility, mechanistic precision, and workflow compatibility for cancer and epigenetics research.

• Palonosetron Hydrochloride: Advances in CINV and RINV Preven

  2026-07-30

  The referenced study by Fabi & Malaguti provides a comprehensive update on palonosetron hydrochloride’s unique pharmacological properties and its clinical impact in preventing chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV). Their analysis highlights palonosetron’s superior receptor affinity, prolonged action, and its evolving role in antiemetic guidelines, shaping best practices for oncology research and clinical care.

• Circular RNA Vaccines: Durable Immunity Against SARS-CoV-2 V

  2026-07-29

  Qu et al. (2022) introduced a circular RNA (circRNA) vaccine platform that encodes the trimeric RBD of the SARS-CoV-2 spike protein, demonstrating superior durability and breadth of immune protection in mice and rhesus macaques compared to conventional mRNA vaccines. This study suggests circRNA vaccines may offer a robust approach to counter emerging SARS-CoV-2 variants and informs future vaccine design strategies.

• Dissecting Aneugenic Mechanisms: Insights from 27 Reference

  2026-07-29

  This study introduces a robust, tiered molecular assay that defines the primary mechanisms underlying chemical-induced aneugenicity in vitro. By differentiating tubulin stabilization, destabilization, and mitotic kinase inhibition—especially Aurora kinase inhibition—it advances mechanistic clarity for genotoxicity assessment and has direct implications for cancer biology and drug development.

• Brain-to-Spinal Circuits Regulate Mechanical Allodynia Later

  2026-07-28

  Huo et al. (2023) identify a specific brain-to-spinal circuit that governs both the laterality and duration of mechanical allodynia in mice. Their findings reveal how descending neural pathways from the lateral parabrachial nucleus and hypothalamus modulate pain hypersensitivity, offering new insight into the control of chronic pain states.

• YM-155 Hydrochloride: Survivin Inhibitor Workflows & Trouble

  2026-07-28

  YM-155 hydrochloride enables robust, selective modulation of the apoptosis pathway, making it a cornerstone for survivin inhibitor research in cancer models. This article details practical protocol parameters, advanced applications, and troubleshooting insights, with actionable guidance drawn from the latest in vitro drug response methodologies.

• Optimizing O-GlcNAcylation Research with OSMI-1 (SKU B7923)

  2026-07-27

  This article provides practical, scenario-driven guidance for using OSMI-1 (SKU B7923), a cell-permeable O-GlcNAc transferase inhibitor, to overcome reproducibility and data interpretation challenges in protein O-GlcNAc modification studies. By integrating quantitative benchmarks and evidence-based troubleshooting, it supports biomedical researchers aiming for robust, reliable outcomes in cell viability and placental biology assays.

• Mtb Chp2–BMX Kinase Axis Disrupts Lysosomal Acidification

  2026-07-27

  This study uncovers how Mycobacterium tuberculosis (Mtb) secretes Chp2 to manipulate host BMX kinase, leading to phosphorylation of ATP6V1E1 and inhibition of lysosomal acidification. The findings reveal a novel host-pathogen interaction mechanism with implications for host-directed tuberculosis therapies.

450 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page